Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.
Surgical oncologist Kelly K. Hunt, of MD Anderson Cancer Center, discusses how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and the role of sentinel lymph node dissection in the neoadjuvant setting.
First-line treatment with Tykerb and a taxane failed to improve progression-free survival versus Herceptin plus a taxane in patients with HER2-positive metastatic breast cancer.
Inflammatory breast cancer survivor, Terry Arnold, shares her story of diagnosis and survivorship.
As a side effect of breast cancer treatment, many women develop lymphedema in the arm and upper body.
A new study hopes to gain some clarity on what causes some breast cancer patients to feel "foggy" when receiving chemotherapy.
Josh D. Lauring, of Johns Hopkins Medicine, is interested in identifying the genetic changes that drive breast cancer growth in order to determine novel therapeutic targets for drug development and ultimately improve outcomes for patients with breast cancer.
According to a recent analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than the general population, particularly if they receive adjuvant radiation therapy.
Cancer research groups, Apple and breast cancer organizations partner to accelerate survivorship research.
CURE editor-in-chief and breast oncologist, Debu Tripathy, reviews the top breast cancer research highlights from 2014.
Living with advanced cancer has shifted how I view the passage of time and the growth of my children.
MBCN offers advice for finding financial assistant for medical costs, daily living expenses and transportation to treatment.
Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Debu Tripathy, editor-in-chief of CURE magazine and breast oncologist, discusses genetic testing from the 32nd annual Miami Breast Cancer Conference.
A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype called metaplastic breast cancer, was one of the top studies presented at the Miami Breast Cancer Conference this year.
When a group of metastatic lung cancer patients took on the National Comprehensive Cancer Network and won.
Debu Tripathy, CURE's editor-in-chief, reports on surgical research updates announced at the Miami Breast Cancer Conference held in late February.
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
The management of patients with hormone receptor (HR)-positive breast cancer continues to evolve, with phase 3 studies shedding light on the length of adjuvant anti-estrogen therapy, a novel treatment gaining approval, and new trials exploring combination strategies.
Worrying and cancer go hand-in-hand. It's possible to take a step back from excessive worrying and give yourself a break.
The addition of Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel as a first-line therapy for metastatic HER2-positive breast cancer improved overall survival (OS) by nearly 16 months, according to findings from the phase 3 CLEOPATRA study.
Talk with almost any cancer survivor, and he or she is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory. A review of the research shows how we're focusing on the problem.
Throughout her treatment for breast cancer, TV personality Joan Lunden has advocated for patients like herself—while drawing strength from their support.
